1
|
Benedetti M, De Caterina R, Bionda A, Gardinali M, Cicardi M, Maffei S, Gazzetti P, Pistolesi P, Vernazza F, Michelassi C, Giordani R, Salvatore L. Blood - Artificial Surface Interactions during Cardiopulmonary Bypass. Int J Artif Organs 2018. [DOI: 10.1177/039139889001300808] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Evaluation of the biocompatibility of four different types of oxygenator (bubble, membrane, hollow fibre and ‘hybrid’) was performed on 26 patients undergoing cardiopulmonary bypass during elective coronary surgery. More platelet derangement and an increased degree of hemolysis, revealed by higher plasmatic concentration of beta-thromboglobulin, platelet factor 4 and plasmatic free hemoglobin (p < 0.05), was seen when using the bubble oxygenator. Damage to blood cells was minimal with the membrane oxygenator while the ‘hybrid’ and the hollow fibre oxygenators proved to rank at an intermediate level. Complement activation at the beginning of the cardiopulmonary bypass occurred via the alternative pathway as demonstrated by C3adesarg increase (up to nine times) without a concomitant elevation of C4adesarg. Cardiopulmonary bypass complement activation was quantitatively similar with all the oxygenators. A further activation via the classical pathway occured in all the patients after protamine injection. Consistent differences as far as clinical and biological effects exist among the various commercially available cardiopulmonary bypass apparatus; our study provides guidelines for the evaluation and selection of devices which might reduce postoperative sequelae.
Collapse
Affiliation(s)
| | | | - A. Bionda
- II Medical Clinic, University of Pisa, Pisa, Milano - Italy
| | - M. Gardinali
- V Medical Clinic, University of Milano, Milano - Italy
| | - M. Cicardi
- V Medical Clinic, University of Milano, Milano - Italy
| | - S. Maffei
- Department of Cardiac Surgery, Milano - Italy
| | - P. Gazzetti
- CNR Institute of Clinical Physiology, Milano - Italy
| | - P. Pistolesi
- II Medical Clinic, University of Pisa, Pisa, Milano - Italy
| | - F. Vernazza
- Department of Cardiac Surgery, Milano - Italy
| | - C. Michelassi
- CNR Institute of Clinical Physiology, Milano - Italy
| | - R. Giordani
- II Medical Clinic, University of Pisa, Pisa, Milano - Italy
| | | |
Collapse
|
2
|
|
3
|
Smith BR, Rinder HM, Rinder CS. Cardiopulmonary Bypass. Platelets 2007. [DOI: 10.1016/b978-012369367-9/50821-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
4
|
Mueller XM, Jegger D, Augstburger M, Horisberger J, von Segesser LK. Poly2-methoxyethylacrylate (PMEA) coated oxygenator: an ex vivo study. Int J Artif Organs 2002; 25:223-9. [PMID: 11999195 DOI: 10.1177/039139880202500309] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
UNLABELLED PMEA is a hydrophilic polymer coating with a unique design that minimizes the adsorption and denaturation of proteins and blood cells. This study compares thrombus resistance, blood path resistance, thrombocyte profile, and blood trauma of the PMEA coated Capiox membrane oxygenator (Terumo, Japan) vs. an uncoated version. METHOD Six calves (mean bodyweight: 75.3 +/- 4.5kg) were placed on cardiopulmonary bypass for 6 hours and randomly assigned to the coated or uncoated oxygenator, with a low heparinisation protocol (ACT > 180s). RESULTS Macroscopically, red staining was observed in all uncoated oxygenators, and in none of the coated ones. Inlet pressure was significantly higher in the uncoated group (at 1 h: 279 +/- 25 vs. 175 +/- 11mmHg, p < 0.01 and at 6h: 217 +/- 10 vs. 171(8mmHg, p < 0.01). Thrombocyte count values (corrected for hematocrit and normalized by prebypass values) were significantly higher in the coated group (at 1 h: 76 +/- 6 vs. 53 +/- 13%, p < 0.01 and at 6 h: 70 +/- 6 vs. 44 +/- 26%, p < 0.01). Plasma hemoglobin was below 100mg/L in both groups throughout the experiments. CONCLUSIONS When compared with uncoated oxygenator, PMEA coated oxygenator exhibited increased thrombus resistance with lower inlet pressure and lower thrombocyte consumption. In both groups, trauma to red cells was minimal, emphasizing the efficient design of this type of oxygenator.
Collapse
Affiliation(s)
- X M Mueller
- Department of Cardio-Vascular Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
| | | | | | | | | |
Collapse
|
5
|
Mueller XM, Tevaearai HT, Jegger D, Tucker O, von Segesser LK. Are standard human coagulation tests suitable in pigs and calves during extracorporeal circulation? Artif Organs 2001; 25:579-84. [PMID: 11493280 DOI: 10.1046/j.1525-1594.2001.025007579.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The thrombogenicity of membrane oxygenators as well as clotting parameters profiles, using standard human clotting tests, was analyzed in calves and pigs during 6 h perfusion. Three calves and 3 pigs were connected to extracorporeal circulation with standard heparinization. Blood samples were taken for coagulation variables throughout perfusion, and oxygenators were examined for clot deposits at the end of the experiment. Two out of 3 oxygenators of the calf group presented clot deposits while none in the pig group did. Baseline coagulation variables of pigs showed values similar to those of humans while neither extrinsic nor intrinsic pathways could be activated in calves with standard human coagulation tests. The calf model, in conclusion, was confirmed to be a difficult model for the testing of extracorporeal circulation device resistance to thrombus formation, which is, however, not reflected by standard human coagulation tests. The pig model is a better model in which both coagulation pathways could be activated with standard human coagulation tests.
Collapse
Affiliation(s)
- X M Mueller
- Clinic for Cardiovascular Surgery, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland.
| | | | | | | | | |
Collapse
|
6
|
Suzuki Y, Malekan R, Hanson CW, Niewiarowski S, Sun L, Rao AK, Edmunds LH. Platelet anesthesia with nitric oxide with or without eptifibatide during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1999; 117:987-93. [PMID: 10220694 DOI: 10.1016/s0022-5223(99)70380-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVE This study tested the hypothesis that nitric oxide or nitric oxide and eptifibatide (Integrilin) reversibly inhibit platelet activation and consumption during cardiopulmonary bypass and rapidly restore platelet numbers and function after bypass. METHODS Nitric oxide, a short-acting, reversible platelet inhibitor, was studied with and without eptifibatide, a short-acting, reversible glycoprotein IIb/IIIa inhibitor, in 21 baboons that underwent 60 minutes of normothermic cardiopulmonary bypass with peripheral cannulas. A control group, a group that received 80 ppm nitric oxide, and a group that received both nitric oxide and eptifibatide were studied. Blood samples were obtained at several time points to determine platelet count, aggregation in response to adenosine diphosphate, and levels of beta-thromboglobulin, prothrombin fragment 1.2, and thrombin-antithrombin complex. Template bleeding times were measured before and at 4 intervals after cardiopulmonary bypass. RESULTS Both nitric oxide and the combination of the 2 drugs significantly attenuated platelet consumption, improved postbypass function, and reduced plasma beta-thromboglobulin release with respect to values in control animals. Both nitric oxide and the combination restored baseline bleeding times 55 minutes after cardiopulmonary bypass ended. No significant differences between nitric oxide and the combination were found for any measurement. CONCLUSION Nitric oxide with or without eptifibatide protects platelets during cardiopulmonary bypass and accelerates restoration of normal bleeding times after operation in a baboon model. Although nitric oxide and eptifibatide reversibly inhibit platelets by different mechanisms, in the absence of a wound no synergistic effect was demonstrated.
Collapse
Affiliation(s)
- Y Suzuki
- Harrison Surgical Research Laboratories, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, USA
| | | | | | | | | | | | | |
Collapse
|
7
|
Wernovsky G, Wypij D, Jonas RA, Mayer JE, Hanley FL, Hickey PR, Walsh AZ, Chang AC, Castañeda AR, Newburger JW, Wessel DL. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 1995; 92:2226-35. [PMID: 7554206 DOI: 10.1161/01.cir.92.8.2226] [Citation(s) in RCA: 738] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND The neurological morbidity associated with prolonged periods of circulatory arrest has led some cardiac surgical teams to promote continuous low-flow cardiopulmonary bypass as an alternative strategy. The nonneurological postoperative effects of both techniques have been previously studied only in a limited fashion. METHODS AND RESULTS We compared the hemodynamic profile (cardiac index and systemic and pulmonary vascular resistances), intraoperative and postoperative fluid balance, and perioperative course after deep hypothermia and support consisting predominantly of total circulatory arrest or low-flow cardiopulmonary bypass in a randomized, single-center trial. Eligibility criteria included a diagnosis of transposition of the great arteries and a planned arterial switch operation before the age of 3 months. Of the 171 patients, 129 (66 assigned to circulatory arrest and 63 to low-flow bypass) had an intact ventricular septum and 42 (21 assigned to circulatory arrest and 21 to low-flow bypass) had an associated ventricular septal defect. There were 3 (1.8%) hospital deaths. Patients assigned to low-flow bypass had significantly greater weight gain and positive fluid balance compared with patients assigned to circulatory arrest. Despite the increased weight gain in the infants assigned to low-flow bypass, the duration of mechanical ventilation, stay in the intensive care unit, and hospital stay were similar in both groups. Hemodynamic measurements were made in 122 patients. During the first postoperative night, the cardiac index decreased (32.1 +/- 15.4%, mean +/- SD), while pulmonary and systemic vascular resistance increased. The measured cardiac index was < 2.0 L.min-1.m-2 in 23.8% of the patients, with the lowest measurement typically occurring 9 to 12 hours after surgery. Perfusion strategy assignment was not associated with postoperative hemodynamics or other nonneurological postoperative events. CONCLUSIONS After heart surgery in neonates and infants, both low-flow bypass and circulatory arrest perfusion strategies have comparable effects on the nonneurological postoperative course and hemodynamic profile.
Collapse
Affiliation(s)
- G Wernovsky
- Department of Cardiology, Children's Hospital, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Affiliation(s)
- F W Campbell
- Department of Anesthesia, Hospital of the University of Pennsylvania, Philadelphia 19104-4283
| |
Collapse
|
9
|
Jones RL, St Cyr JA, Tornabene SP, Lauber B, Harken AH. Reversible pulmonary hypertension secondary to mitral valvular disease as an indication for extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 1991; 5:494-7. [PMID: 1932654 DOI: 10.1016/1053-0770(91)90126-e] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- R L Jones
- Department of Anesthesiology, University of Colorado Health Sciences Center, Denver 80262
| | | | | | | | | |
Collapse
|
10
|
Stahl RF, Fisher CA, Kucich U, Weinbaum G, Warsaw DS, Stenach N, O’Connor C, Addonizio VP. Effects of simulated extracorporeal circulation on human leukocyte elastase release, superoxide generation, and procoagulant activity. J Thorac Cardiovasc Surg 1991. [DOI: 10.1016/s0022-5223(19)36757-1] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Affiliation(s)
- M B Starling
- Cardiology Department, Green Lane Hospital, Auckland, New Zealand
| | | |
Collapse
|
12
|
Paul Addonizio V. Platelet Function in Cardiopulmonary Bypass and Artificial Organs. Hematol Oncol Clin North Am 1990. [DOI: 10.1016/s0889-8588(18)30510-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Teoh KH, Weisel RD, Ivanov J, Teasdale SJ, Glynn MF. Dipyridamole for coronary artery bypass surgery. THROMBOSIS RESEARCH. SUPPLEMENT 1990; 12:91-9. [PMID: 2082492 DOI: 10.1016/0049-3848(90)90445-i] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A randomized trial to compare the effects of oral and intravenous dipyridamole was conducted in 58 patients undergoing coronary artery bypass graft (CABG) surgery. Preoperative oral administration of dipyridamole resulted in lower plasma drug concentrations in the early postoperative period than perioperative intravenous administration. Postoperative platelet counts were highest in the patients receiving intravenous dipyridamole, intermediate in those receiving oral dipyridamole and lowest in the control group. Postoperative blood loss was significantly reduced with both oral and intravenous dipyridamole. A second randomized trial was conducted in an additional 40 patients undergoing CABG surgery to evaluate the effects of dipyridamole on myocardial platelet and leukocyte deposition and the cardiac release of thromboxane. Twenty patients received intravenous dipyridamole perioperatively. Autologous platelets and leukocytes were labeled with 111In and 99mTc respectively and were infused before release of the crossclamp. Myocardial biopsies were obtained after aortic declamping and indicated that platelets and leukocytes were deposited in the myocardium during reperfusion. Dipyridamole reduced both platelet and leukocyte deposition. Cardiac release of thromboxane B2 occurred in the early postoperative period and was reduced by dipyridamole. In conclusion, dipyridamole preserved platelets and reduced postoperative bleeding and blood product transfusions in patients undergoing CABG surgery. Dipyridamole also reduced cardiac platelet deposition and thromboxane release and may reduce perioperative ischemic injury.
Collapse
Affiliation(s)
- K H Teoh
- Division of Cardiovascular Surgery, Toronto General Hospital, Canada
| | | | | | | | | |
Collapse
|
14
|
VanWinkle WB. Invited letter concerning: Assessment of mitochondrial damage in ischemia. J Thorac Cardiovasc Surg 1989. [DOI: 10.1016/s0022-5223(19)34306-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
|
16
|
Spyt TJ, Wheatley DJ, Walker ID, Davidson JF, MacArthur K, Martin W. Placebo-controlled study of Iloprost (ZK 36374) in cardiopulmonary bypass surgery. Perfusion 1988. [DOI: 10.1177/026765918800300303] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The effects of infusion of Iloprost (ZK 36374), a prostacyclin analogue, on platelet function, postoperative blood loss and microaggregate deposition on filters and oxygenators were studied in patients undergoing routine coronary operations. In this double-blind randomized study of 50 male patients, 25 received Iloprost and 25 a placebo. Platelet deposition was assessed using Indium-labelled platelets. Comparison of Iloprost and placebo groups showed the mean number of platelets to be significantly higher in the Iloprost group at the end of cardiopulmonary bypass and in early postoperative recovery. Similarly, spontaneous aggregation of platelets was higher in the placebo group. The mean percentages of platelets sequestrated in the extracorporeal circuit were significantly higher in the placebo group. There was no difference in either the amount or pattern of postbypass bleeding between Iloprost and the control patients. Infusion of the tested drug was responsible for significant hypotension, which was correctable with fluid administration alone. Thus, Iloprost diminishes the fall in circulatory platelet count during cardiopulmonary bypass, preserves platelet function, diminishes platelet deposition on filters and oxygenators, but also causes arterial hypotension.
Collapse
|
17
|
Rocha E, Llorens R, Páramo JA, Arcas R, Cuesta B, Trenor AM. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation 1988; 77:1319-23. [PMID: 3286039 DOI: 10.1161/01.cir.77.6.1319] [Citation(s) in RCA: 80] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
It has been suggested that desmopressin acetate (DDAVP) administration reduces blood loss after cardiac surgery. We have investigated the effect of DDAVP administration in a double-blind, randomized, prospective trial including 100 patients placed on cardiopulmonary bypass during surgery. Fifty patients received 0.3 micrograms/kg DDAVP and 50 patients received a placebo administered in a 50 ml saline solution over 15 min when cardiopulmonary bypass had been concluded. Results showed no significant differences either in total blood loss per square meter (458 +/- 206 ml in the DDAVP group vs 536 +/- 304 ml in the placebo group) or in necessity for red cell transfusions (1642 +/- 705 ml in the DDAVP group vs 1574 +/- 645 ml in the placebo group) in the first 72 hr after surgery. Only intraoperative blood loss per square meter was significantly lower (p less than .02) in the DDAVP group (131 +/- 106 ml) as compared with the placebo group (193 +/- 137 ml). The prolongation of bleeding time and the decrease of factor VIII:C and factor VIII:von Willebrand factor 90 min after treatment were significantly lower (p less than .001) in the DDAVP group as compared with the placebo group. We conclude that the administration of DDAVP in patients placed on cardiopulmonary bypass during surgery does not reduce total blood loss and is only effective in reducing intraoperative bleeding.
Collapse
Affiliation(s)
- E Rocha
- Hematology and Cardiovascular Surgery Services, University Clinic, University of Navarra, Pamplona, Spain
| | | | | | | | | | | |
Collapse
|
18
|
Mezzano D, Aranda E, Urzúa J, Lema G, Habash J, Irarrázabal MJ, Pereira J. Changes in platelet beta-thromboglobulin, fibrinogen, albumin, 5-hydroxytryptamine, ATP, and ADP during and after surgery with extracorporeal circulation in man. Am J Hematol 1986; 22:133-42. [PMID: 2422929 DOI: 10.1002/ajh.2830220204] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Surgery with extracorporeal circulation (ECC) is associated with transient alterations of platelet function whose pathogenic mechanisms are not completely understood. To define further the platelet abnormalities, we determined the changes in platelet content of several granule-associated substances during and after ECC in patients subjected to aortocoronary bypass surgery. Platelet beta-thromboglobulin (beta-TG) decreased to 79.8% of the preoperative level at the end of ECC (p less than 0.01) and, as expected, did not recover 1 hr after the end of surgery. Platelet fibrinogen and albumin decreased to 67.9% (p less than 0.01) and to 29.8% (p less than 0.01) of baseline, respectively. However, 1 hr after surgery, platelet fibrinogen rose to 92% and albumin to 55.5% of baseline, denoting that during the recovery from ECC, platelets incorporate some plasma proteins. During ECC, platelet 5-hydroxytryptamine (5-HT) and total ATP and ADP decreased to 50.8% (p less than 0.01), 63.2% (p less than 0.01), and 69.9% (p less than 0.01) of their respective preoperative values, indicating dense body release. One hour after surgery, ATP recovered to 83.8%, suggesting that previous depletion compromised also the metabolic pool of adenine nucleotides. In summary, Our results confirm and extend previous observations demonstrating alpha-granule release during ECC. Platelets undergoing ECC can incorporate plasma proteins as evidenced by the rapid increase of platelet fibrinogen and albumin after bypass. Although the mechanisms of this increase and site of storage of the exogenous substances are unknown, this observation justifies further studies to determine if internalization of plasma proteins, especially fibrinogen, may take place in physiological conditions. Dense body depletion with transient storage pool deficiency appears to be a component of the reduced platelet function during ECC. Consumption of metabolic ATP with alteration of platelet energy metabolism may further impair platelet function, contributing to the bleeding episodes observed during surgery with ECC.
Collapse
|
19
|
Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson L, Donovan A, Gaffney T, Bertele V, Troll J. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986; 314:1402-6. [PMID: 3517650 DOI: 10.1056/nejm198605293142202] [Citation(s) in RCA: 416] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Bleeding after cardiopulmonary bypass remains a cause for concern, requiring reexploration of the chest in approximately 3 percent of patients who have had operations on the heart. We examined the possibility that this problem might be alleviated by desmopressin acetate (DDAVP), which increases the plasma level of von Willebrand factor and improves hemostasis in mild hemophilia and other conditions associated with defective platelet function. In a double-blind, prospective, randomized trial, we studied the effect of intraoperative desmopressin acetate in 70 patients undergoing various cardiac operations requiring cardiopulmonary bypass. Patients undergoing uncomplicated primary coronary-artery bypass grafting were not included. The drug significantly reduced mean operative and early postoperative blood loss (1317 +/- 486 ml in the treated group vs. 2210 +/- 1415 ml in the placebo group); of the 14 patients whose 24-hour blood loss exceeded 2000 ml, 11 had received the placebo. Plasma levels of von Willebrand factor were higher after desmopressin acetate than after placebo. Patients with the most bleeding had relatively low levels of von Willebrand factor before operation, suggesting a role for this factor in the hemorrhagic tendency induced by extracorporeal circulation. There were no untoward side effects of desmopressin acetate. We conclude that the administration of desmopressin acetate can be recommended to reduce blood loss in patients undergoing complex cardiac operations. The beneficial effect of the drug on hemostasis after cardiopulmonary bypass may be related to its effect on von Willebrand factor.
Collapse
|
20
|
Abstract
Platelets contain three types of secretory organelles: the dense granules, the alpha granules, and the lysosomes. Most of the proteins secreted from platelets are stored in the alpha granules, whereas the dense granules contain substances such as adenine nucleotides, serotonin, Ca++, and inorganic pyrophosphate types as well as a heparatinase. Three of the secreted alpha granule proteins have been measured by radioimmunoassay and it has been suggested that levels of these proteins in patient plasmas provide an index of in vivo platelet activation and secretion. These three are beta-thromboglobulin, platelet factor 4, and thrombospondin. In this chapter the chemistry of these proteins will be considered briefly, as will their clearance from the circulation, and then the clinical studies will be reviewed critically. Since radioimmunoassays were developed for these proteins (the first was reported in 1975), there has been a profusion of reports on levels of one or another of these proteins in a wide range of disease states, and these reports have indicated secreted platelet protein levels ranging from normal to grossly elevated in a given disease state. Possible reasons for such variability will be discussed.
Collapse
|
21
|
Sollevi A, Torssell L, Fredholm BB, Settergren G, Blombäck M. Adenosine spares platelets during cardiopulmonary bypass in man without causing systemic vasodilatation. SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY 1985; 19:155-9. [PMID: 4048886 DOI: 10.3109/14017438509102711] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The effect of infusing adenosine during cardiopulmonary bypass (CPB) on platelet count and mean arterial blood pressure (MABP) was studied in 13 patients (age 42-74), with 12 patients (age 47-66) as controls. Adenosine infusion (0.1 mg/kg/min in a central vein) caused a ten- to twentyfold increase of the adenosine concentration in the venous blood to the oxygenator, while the arterial levels were close to basal values (0.3 +/- 0.1 microM). The platelet count was significantly higher in the treated than in the placebo group during and 30 min after CPB, but not on the postoperative day. The groups did not differ with regard to the postoperative blood loss from tube drainage. Adenosine did not cause major systemic vasodilation (MABP less than 30 mmHg) in any case, and the blood pressure levels showed no intergroup difference during CPB. However, seven control patients but none in the adenosine group required vasodilator treatment (sodium nitroprusside) during CPB to prevent MABP from exceeding 70 mmHg. We conclude that adenosine infusion during CPB in man spares platelets, with minor changes in blood pressure.
Collapse
|
22
|
Heinrich D, Schleussner E, Wagner WL, Sellmann-Richter R, Hehrlein FW. Prostacyclin in aortocoronary bypass surgery: a double-blind, placebo-controlled study. Thromb Res 1983; 32:409-26. [PMID: 6362060 DOI: 10.1016/0049-3848(83)90093-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
In a double-blind, placebo-controlled trial of 40 patients requiring aortocoronary vene transplant surgery, prostacyclin (PGI2) was infused in a dose of 8 ng/kg/min throughout cardiopulmonary bypass. When compared with the placebo-group, the patients treated with PGI2 were found to have significantly higher platelet counts 60(2) and 90 minutes after onset of extra-corporeal circulation (EC). Although this platelet preservation by PGI2 was accompanied by less degranulation of alpha-granula, total antithrombin III (AT III) as well as active AT III and factor Xa inhibitory activity did show comparable results in both treatment groups. In the early phase of EC coagulation factors (fibrinogen, prothrombin and factor VII) exhibited a trend in favour of higher plasma levels in the PGI2-treated group. The same results were found for plasminogen. F VIII-related antigen and complement factors (C3, C4, C3 activator) did not show any difference between the two treatment groups. Bleeding times, blood loss and renal function also did not exhibit any significant differences between the two groups of patients. Except for one control (60 minutes after onset of EC) hemodynamic parameters were not significantly different between the two patient groups. Whether the trend in favour of a lower mortality in PGI2-treated patients can be confirmed, will be up to further studies with greater numbers of patients.
Collapse
|
23
|
Ditter H, Heinrich D, Matthias FR, Sellmann-Richter R, Wagner WL, Hehrlein FW. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of beta-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin F1 alpha and heparin. Thromb Res 1983; 32:393-408. [PMID: 6197766 DOI: 10.1016/0049-3848(83)90092-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
A randomized double-blind study was carried out on 40 male patients requiring aorto-coronary bypass surgery. 20 patients received a constant dose of 8 ng kg-1 min-1 of prostacyclin (PGI2), beginning two minutes before extracorporeal circulation (ECC) and ending together with ECC. Compared to the placebo-treated patient group (n = 20), PGI2-treatment significantly reduced the ECC-induced release of platelet alpha-granule proteins, beta-thromboglobulin (1178 ng/ml vs. 1926 ng/ml) and platelet factor 4 (837 ng/ml vs. 1245 ng/ml) into plasma (mean of max. values). Furthermore the decrease of platelet counts during ECC was less pronounced in PGI2-treated patients. Application of PGI2 had no effect on the increase in thromboxane B2 (TxB2) plasma levels, which amounted to 0.6 ng/ml at the end of ECC. PGI2-treatment resulted in significantly elevated plasma concentrations of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) (2.1 ng/ml) throughout the infusion off prostacyclin. 6-keto-PGF1 alpha plasma levels increased up to 1.2 ng/ml in the control group patients, indicating a stimulation of endogenous PGI2 formation during ECC.
Collapse
|
24
|
Aznavoorian SA, Utsunomiya T, Krausz MM, Cohn LH, Shepro D, Hechtman HB. Prostacyclin inhibits 5-hydroxytryptamine release but stimulates thromboxane synthesis during cardiopulmonary bypass. PROSTAGLANDINS 1983; 25:557-70. [PMID: 6348886 DOI: 10.1016/0090-6980(83)90028-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The antiaggregating agent prostacyclin (PGI2) was infused into ten dogs during cardiopulmonary bypass (CPB) to minimize thrombocytopenia and platelet dysfunction. The animals were anesthetized, placed on mechanical ventilation and underwent thoracotomy. After heparinization with 300 u/kg, animals were assigned to control (n=5) or PGI2 treated groups (n=5). Thoracotomy and then CPB decreased platelet numbers to below 30,000/mm3 (p less than 0.05) and fibrinogen to less than 150 mg/dl (p less than 0.05). PGI2 at 100 ng/kg.min was infused for the 2 h period of CPB. PGI2 infusion did not prevent these changes, but did prevent platelet serotonin release. In the control group after CPB, platelet serotonin fell from the baseline value of 1.11 microgram/10(9) to 0.35 microgram/10(9) platelets (p less than 0.05). In contrast, PGI2 treatment resulted in a serotonin increase to 2.27 micrograms/10(9) platelets (p less than 0.05). Thromboxane B2 concentrations of platelets and plasma rose during CPB (p less than 0.05). Surprisingly, PGI2 infusion accentuated this rise in platelet and plasma thromboxane B2 (p less than 0.05). These data indicate that during CPB, an infusion of PGI2: 1) does not prevent thrombocytopenia; 2) increases platelet serotonin uptake despite, 3) an associated rise in platelet and plasma thromboxane B2.
Collapse
|
25
|
|
26
|
|
27
|
Abstract
Extensive contact between blood and the synthetic surfaces of an extra-corporeal circuit causes thrombocytopenia, release of platelet granular contents, initiation of thromboxane synthesis, disruption of subcellular architecture and loss of platelet sensitivity to standard platelet agonists. All too frequently, these adverse platelet alterations are reflected in a prolongation of the post-operative bleeding time and excessive blood loss which precludes implementation of long-term circulatory assist devices. Unfortunately, a truly biocompatible material does not exist and efficiency of gas transport demands haemodynamic designs which actually promote platelet injury. Although manipulation of surface properties and mechanical improvements in circuitry have managed to reduce platelet-surface interactions, the ultimate potential of these manoeuvres may be limited. Synthetic surfaces and soluble agonists, however, appear to modulate similar pathways suggesting that temporary platelet inhibition might provide significant protection by preserving the morphological and functional integrity of circulating platelets during contact with extracorporeal circuits.
Collapse
|
28
|
Walker ID, Davidson JF, Faichney A, Wheatley DJ, Davidson KG. A double blind study of prostacyclin in cardiopulmonary bypass surgery. Br J Haematol 1981; 49:415-23. [PMID: 6457624 DOI: 10.1111/j.1365-2141.1981.tb07244.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
In a double-blind placebo-controlled trial of 48 patients requiring open heart surgery, prostacyclin (PGI2) was infused in a dose of 20 ng/kg/min throughout cardiopulmonary bypass. When compared with the placebo group, the patients given active PGI2 were found to have significantly higher platelet counts from 30 min after commencement of bypass and in the immediate post-operative period, and to have significantly less elevation of the platelet secretory proteins, beta thromboglobulin and platelet factor 4 during bypass. The mean weight increase in the arterial line filters was significantly greater in the placebo-treated patients than in the PGI2 group. It is suggested that infused PGI2 decreases platelet activation during cardiopulmonary bypass and that further studies are required to establish its clinical value in this situation.
Collapse
|
29
|
Cella G, Vittadello O, Gallucci V, Girolami A. The release of beta-thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery. Eur J Clin Invest 1981; 11:165-9. [PMID: 6168469 DOI: 10.1111/j.1365-2362.1981.tb01836.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Cardiopulmonary bypass is extremely damaging to platelets and it causes a quantitative and qualitative alteration in their functions. We evaluated the release of two platelet-specific proteins, beta-thromboglobulin (beta TG) and platelet factor 4 (PF4), in patients who underwent extracorporeal circulation for open heart surgery. A parallel release (basal value beta TG: 119.6 ng/ml, PF4 30 ng/ml) was present for both proteins in a time dependent fashion until the end of extracorporeal circulation. High average levels were observed in patients in whom the bypass was stopped after about 1 h (beta TG 1606 ng/ml, PF4 745 ng/ml) and similarly in those in whom the bypass was stopped after about 2 h (beta TG 1540 ng/ml, PF 4754 ng/ml). No correlation was found either between the level of PF4 and the additional heparin administered after the initial standard dose (r = 0.29, P greater than 0.10) and between the level of PF4 and the amount of heparin consumed during the bypass (r = 0.05, P greater than 0.5).
Collapse
|
30
|
|
31
|
|
32
|
Farah AE, Rosenberg F. Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors. Br J Clin Pharmacol 1980; 10 Suppl 2:261S-278S. [PMID: 6776977 PMCID: PMC1430184 DOI: 10.1111/j.1365-2125.1980.tb01809.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
1 The ubiquitous actions of the cyclo-oxygenase inhibitors are described. 2 These include the inhibitory effect on prostaglandin synthesis and the direct effect of aspirin on lymphocytes and their ability to produce lymphokines. 3 Aspirin reduces some types of platelet aggregation possibly involving inhibition of the precursors of thromboxane A2 and prostacyclin. 4 The therapeutic implications in relation to transient ischaemic attacks, coronary artery disease and reno-allograft rejection are discussed. 5 The beneficial and adverse effects on the gastro-intestinal tract are described. 6 The effects of aspirin-like drugs on the genito-urinary tract are described with particular reference to their adverse effects on labour and their therapeutic effect on dysmenorrhoea.
Collapse
|